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ABSTRACT
Purpose: To determine the dosimetric accuracy of a dose reconstruction method used for
verification of helical tomotherapy delivery for three different clinical sites.
Methods and Materials: A delivery verification and dose reconstruction method has been
applied to helical tomotherapy treatment plans of three different treatment sites (head & neck,
prostate and lung). Treatment plans were generated on a cylindrical measurement phantom
(TomoPhantom) using contours, prescriptions and planning objectives taken from clinical patient
plans of the three sites. Film and ion chamber measurements were made for each plan with and
without intentional changes in the machine output [-4% to 4%] or leaf open times [-30 ms to +30
ms] to the planned delivery.
A TomoTherapy delivery verification tool uses pulse-by-pulse machine CT detector and
transmission ion chamber data, extracted at the conclusion of each delivery, to determine the
incident energy fluence delivered for each projection. Dose reconstruction was calculated by
simulating the delivered energy fluence onto the planning CT. The reconstructed doses were
compared with both the measured and planned dose distributions.
Results: Measured dose variations for repeated daily deliveries were small, typically within 2%.
Greatest differences between the measured dose and planned dose occurred when intentional
changes in leaf open times (±30 ms) were made to the delivery. Measured doses from all
deliveries were well predicted by the dose reconstruction method, which demonstrated
agreement for point doses to within 2%. The dose reconstruction method also demonstrated
acceptable agreement with the film dose measurements for all three plans. Comparison of film
versus reconstructed dose for all cases showed that over 90% of a selected region of interest had
a gamma index of less than 1.

x

Conclusion: The method of dose reconstruction based on machine detector data can account for
daily variations in the delivered dose due to machine error. Dosimetric accuracy for the method
is acceptable within clinical standards.

xi

CHAPTER 1. INTRODUCTION
1.1

Background and Significance
1.1.1

Goals and Advances in Radiation Therapy

The goal of radiation therapy is to deliver as much dose as necessary to destroy cancerous cells
while minimizing or limiting the dose to normal healthy tissues. It begins at the treatment
planning stage where planning target volume (PTV) and organs at risk (OARs) are defined1, 2 on
a treatment planning CT image dataset of a patient taken while in treatment position. The PTV
covers the gross tumor volume (GTV) with additional margin to account for microscopic cancer,
effects of organ and patient movements, radiation beam inaccuracy and set-up uncertainty
(Figure 1). OARs are normal healthy tissues near the PTV that have set tolerances for radiation
dose and are the limiting factors during treatment planning. Dose objectives for PTVs and
OARs are influenced by the overall treatment objective (curative or palliative). Once PTV and
OARs have been determined, the next step is to determine which modality of treatment is best
suited to achieve the goal of a favorable outcome for the patient. This includes the method of
treatment (brachytherapy, external beam, intra-operative, etc.), the type of radiation (photons,
electrons, protons, etc.) and energy selection.

Figure 1. Illustration of PTV (blue) coverage that includes the GTV (red), microscopic
extension (green) and setup error
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One of the latest advances in radiation delivery is intensity modulated radiation therapy
(IMRT). IMRT is a treatment delivery method that uses optimized non-uniform or modulated
beam intensities to deliver a highly conformal dose distribution within a patient.3, 4 The benefit
of this method is the ability to escalate dose to cancerous cells while decreasing the maximum
dose to the surrounding normal tissues. The result is higher tumor control probabilities and/or
lower normal tissue complication probabilities. However, these advantages assume that the
patient’s anatomy is in the same position at the time of treatment as they were during the
treatment planning CT. If the tumor were to shift or change size or shape from the planned
image during treatment delivery, it may not receive the planned radiation dose coverage.
Furthermore, a normal tissue adjacent to the tumor could receive too much dose.
The different ways to deliver an IMRT treatment may be divided into gantry static (i.e.,
multiple field originating from different fixed positions) and gantry dynamic delivery techniques.
Gantry static techniques typically achieve beam modulation through the use of multi-leaf
collimator (MLC), although compensator filters or beam scanning are sometimes used. MLC
leaf positions are adjusted during the treatment to define field shapes or segments. Gantry static
MLC techniques may be further divided into segmental (SMLC), where no radiation is delivered
during leaf movement or dynamic (DMLC), where radiation is delivered during leaf movement.
Gantry dynamic techniques include intensity modulated arc therapy (IMAT) and serial and
helical tomotherapy. Tomotherapy delivery systems use a binary MLC where the leaf positions
are either open or closed at any point in time during the treatment.
The importance that IMRT places on the reproducibility of patient’s position has
motivated developments in image-guided radiation therapy (IGRT). The basis of IGRT is to take
an image of the patient immediately prior to or during the treatment to verify and adjust (if
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necessary) the patient’s position so that he/she is in the same position as the time the planning
image was taken. Obtaining the image in the treatment room can be done by using ultrasound5,
planar x-rays6, kilovoltage CT (kVCT)7, 8 or a megavoltage CT (MVCT)9.
1.2

TomoTherapy
1.2.1

Introduction to the Hi·Art Delivery System

The TomoTherapy Hi·Art delivery system is
one of the latest advancement in radiotherapy that is
capable of both a helical IMRT delivery and a MVCT
IGRT imaging system within the same unit (Figure
2).10 The radiation source used for both treatment and
imaging is a linear accelerator (linac) with nominal
photon beam energies of 6 MV and 3.5 MV,
respectively. The linac rotates on a slip-ring gantry

Figure 2. TomoTherapy
Hi·ART
delivery system

about a fixed axis located 85 cm from the source. The field width in the longitudinal direction is
defined by a pair of collimating jaws that have an adjustable range of 0.6-5.0 cm at the axis of
rotation. The field length in the lateral direction is defined by a 64-leaf binary MLC. Each leaf
of the MLC has a projected width of 6.25 mm at 85 cm from the source which allow for a field
length ranging from 0-40 cm, depending on the number of open leaves.
The imaging detectors for TomoTherapy consist of 738 gas-filled xenon ion chambers
aligned in an arc located on the opposite side of the gantry from the radiation source (Figure 2).
Due to the maximum field length, the MVCT image is limited to a 40 cm field of view (FOV)
instead of the standard 50 cm FOV in a conventional CT. Of the 738 detector channels, only the
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central 640 records exit beam data. The radiation emitted through each open leaf will expose
approximately 7 exit detectors. Detector data are recorded at a rate of 300 pulses per second.
Helical treatment is delivered by moving the couch through the rotating gantry at a
constant speed. The distance the couch moves per gantry rotation is equal to the selected field
width times a user-selected pitch. In the treatment planning process, each rotation is divided into
51 projections, or beams incident from fixed, equally-spaced (approximately every 7°) gantry
angles. In a typical treatment plan, there may be up to several thousand projections, depending
on the length of the PTV(s) and the selected pitch. IMRT delivery is achieved by optimizing the
time each of the 64 leaves remains open per projection in the treatment planning process.
1.2.2

Delivery Subsystem

During treatment, the delivery subsystem software components assist in reading,
translating, and transferring data. One component in particular, the Data Acquisition System
(DAS), translate photon counts from the transmission monitor chambers (located between the
beam source and collimating jaws) and exit detectors into raw detector data. TomoTherapy
stores this data defining the machine state over time in the form of sinograms. A number of
different sinograms are used within the planning and delivery systems, of which a few are
defined here:11
•

Leaf control sinogram: The planned leaf open time versus projection number per
delivery. It has a matrix of 64 by the number of projections (Nproj) for the treatment plan.
The values within this sinogram are fractions of leaf open time per projection.

•

Treatment detector sinogram: The number of counts per pulse (300 pulses/sec) for the
centrally located 640 detectors (out of the 738) and the 3 monitor chambers. This
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sinogram is a matrix of 643 (first 640 are exit CT detector data, last 3 are output data) ×
(300 pulses/sec × delivery time [sec]).
•

Delivery Verification (DV) sinogram: The computed effective leaf open time versus
projection number of a delivered treatment based on the treatment detector sinogram.
The matrix size and value range for each cell are the same as the leaf control sinogram.

It is important to note that there is a leaf control sinogram file for each scheduled fraction within
a plan. Therefore, a plan that has 38 fractions will have 38 leaf control sinogram files.
1.2.3

Image-guided Radiation Therapy (IGRT)

IGRT on TomoTherapy is achieved by initially taking an MVCT scan of the patient in
treatment position prior to a treatment delivery. The MVCT image is overlaid with the planned
image to allow for manual or auto registration. If a shift is needed to align patient into the
planned position, the TomoTherapy Hi·Art system can automatically shift the couch laterally,
longitudinally and vertically. Tilt misalignment in the sagittal plane cannot be corrected by the
system. However, tilt misalignment in the axial plane can be corrected for by offsetting the
delivery angle accordingly.
As mentioned in section 1.2.2, during treatment delivery, the DAS records exit detector
data from the same detectors used for imaging. This data can be used to detect errors in
treatment delivery based on leaf opening time12 and output.13
1.3

Delivery Verification and Dose Reconstruction
1.3.1

Deviations Associated with Treatment Delivery

Although IGRT can be beneficial in properly positioning the patient, it does not correct
for changes in the patient anatomy throughout treatment. Changes to patient anatomy can affect
the delivered dose in two ways. First, the radiation transmission through the patient will be
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altered if the patient changes shape over the course of treatment. This effect may be due to the
patient gaining or losing weight or through tumor shrinkage during the course of treatment.
Second, the radiation dose to the PTV and/or OAR structures may change if they are deformed
relative to their shape at the time of treatment planning.
In addition to changes in patient anatomy, deviations from the planned incident radiation
fluence will also affect the administered dose. Minor deviations (i.e., within machine tolerance)
in machine output will change the delivered dose to the patient. Although IGRT may be used to
determine patient anatomical changes, it does not account for deviations from the planned
delivery associated with the machine.
If daily changes to the delivered dose can be accounted for, the patient’s plan can be
modified during the course of treatment. The process is commonly known as “adaptive
radiotherapy” within the field of practice.14
1.3.2

Methods to Account for Deviated Treatment Delivery

Within the TomoTherapy Hi-Art system, a number of methods to correct for changes in
delivered dose have been proposed and/or implemented. In TomoTherapy Planned Adaptive
(PATM) program, the effect of changes to patient anatomy is accounted for by re-computing the
radiation dose on the daily MVCT taken prior to treatment. This process has been described by
Langen et al.15 Because the MVCT image dataset is smaller (e.g., 40 cm field of view) than the
planning kVCT image dataset (e.g., typically 50 cm), a composite or merged image dataset of the
MVCT and the kVCT is created for the dose recomputation. For the merged image, the kVCT
covers all the image area where the MVCT did not cover relative to the planning image.
Since an MVCT image will be used for dose computation, it is imperative that the image
value-to-density table (IVDT) applied to the MVCT image corresponds to a similar density as
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the planning kVCT image for the same structure. The determination and constancy of IVDTs for
the Hi-Art system has been discussed by Langen et al.15
Although the dose may be recomputed on the daily MVCT image, the clinical impact of
these variations is difficult to quantify unless contour changes in the PTV(s) and OAR(s) have
been accounted. The process of registering a daily treatment image to the planning CT that
account for internal anatomical changes is known as deformable registration.16 Once the new
PTV and OAR have been registered, the cumulative dose to the structures can be recomputed by
applying the planned delivery parameters (machine parameters such as output dose rate, leaf
open sequence, gantry & couch speed and beam field size) onto the registered image. This dose
can then be compared to the planned dose to determine whether a new plan is necessary to
compensate for dose differences in the PTV and OAR. Lu et al.16 discussed the use of
deformable registration for TomoTherapy Hi-Art planning systems.
To account for delivery deviations during treatment, it is necessary to include changes in
machine parameters which affect the delivered dose. This process is sometimes referred to as
delivery verification (DV).11 Kapatoes et al described a technique where the incident energy
fluence (Ψ) can be determined by multiplying the treatment exit-detector signal (s) by the
inverse of a measured transfer matrix (D).

Ψ = D−1 ⋅ s

(1)

With the incident energy fluence from Eq. (1) and an IGRT image, dose may be calculated with
actual, rather than planned, delivery parameters. The incorporation of actual (verified) delivery
parameters into the dose calculation on the daily IGRT image is known as dose reconstruction
(DR)17. Implementing DV and DR into adaptive planning should improve the evaluation of
treatment delivery for patients undergoing IMRT which could lead to improved clinical outcome.
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1.4

Delivery Verification for TomoTherapy
1.4.1

General Concerns

Unlike conventional linear accelerator, TomoTherapy does not deliver a plan according
to the planned monitor units (MUs) which is related to radiation dose. Instead, the delivery is
governed by treatment time that assumes a constant beam output, similar to that of traditional
Co-60 therapy unit (uses an isotope as source of radiation). For the Hi·Art system, the delivered
dose can deviate from the planned dose since TomoTherapy’s beam output are allowed to vary
throughout a treatment delivery by up to 5% over a 5 second interval without interlocking the
machine.18 An illustration of this output variation as seen from a sample patient treatment
delivery is shown in Figure 3, which displays the normalized signals obtained from the three
transmission monitor chambers versus projection number. Notice that the variation is cyclical
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with rotation (51 projections per rotation) and also show a long term drift.

Projection
Figure 3. Normalized output reading from the three transmission monitor
chamber during a typical patient treatment delivery on TomoTherapy
Output deviation may also be due to differences between the planned and actual leaf open
times that are a result of mechanical issues of the 64 leaves and/or their controlling components.
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In the Hi-Art system, the machine delivery tolerance is set to stop treatment if there are four
instances where an individual leaf’s open time is different by more than 32 ms from the planned
leaf opening time. Differences less than this value may affect the delivered dose without
interlocking the machine.
TomoTherapy stores transmission monitor chambers and exit detector data for each
individual treatment delivery in the form of a treatment detector sinogram (defined previously).
The number of counts per pulse recorded by each exit detector is dependent on whether the
leaves are opened or closed, the beam’s radiological path length through all structures (e.g.,
patient, couch, etc.) between the source and the exit detector, and the beam output.
Determination of the energy fluence as a function of off-axis position is possible but requires
knowledge of the patient position and the transmission characteristics of the beam through the
patient.17 However, if we assume that the beam’s profile remains constant during delivery, then
changes in the energy fluence rate through each leaf would be proportional to the signal of the
transmission monitor chambers. For each projection, the total energy fluence that is emitted
through each leaf would then be proportional to the amount of time each leaf remains open.
1.4.2

TomoTherapy DVPA software program

TomoTherapy has developed a delivery verification planned adaptive (DVPATM)
program that can reconstruct the dose based on the DV sinogram and MVCT image data. The
algorithm used for dose calculation in DVPA is the same as that used within the TomoTherapy
treatment planning system (TPS) and assumes a constant beam output for dose calculation. To
account for beam output variations during delivery in the reconstructed dose calculation, DVPA
adjusts each measured leaf open time per projection by the percentage of the difference between
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measured beam output and planned beam output over the period of that projection. The adjusted
leaf open time is defined as the effective leaf open time.
The energy fluence emitted though an open MLC leaf irradiates approximately 7 exit
detectors. Leaf open time per projection for each leaf is determined in DVPA by taking the
average full width-half max (FWHM) of the 5 central detectors’ (of the 7) signal profile (Figure
4). Thus, the delivered energy fluence can be determine by scaling the beam’s intensity up or
down based on the measured output data and use the rise and fall times of the exit detector
signals to determine the leaf open times.12
Raw detector data
140000
120000

Signal

100000
80000

FWHM = leaf open time
60000
40000
20000
0
0
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Pulse #
Figure 4. Signal reading from one exit detector over 300 pulses
Once DVPA determines the effective leaf open time for all projections of a delivery, it
creates the DV sinogram. The energy fluence throughout the delivery is derived from the DV
sinogram and the planned beam output. A reconstructed dose is then computed by applying the
energy fluence onto the MVCT image taken for the delivered plan. Figure 5 illustrates the path
that begins with the acquired exit detector data and ends with the reconstructed dose.
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For this study, we will apply DV and DR method for helical tomotherapy delivery to 3
simulated patient plans (head & neck, prostate and lung) applied to a single phantom image
dataset. Each plan will be delivered with and without intentionally-introduced offsets (within
machine delivery interlocks limit). Comparison between the reconstructed and measured dose
will determine how well the method can account for typical variations of machine performance.

Treatment detector sinogram

Exit detector data

Monitor chamber
data

Leaf open time

Effective
Leaf open time
DV sinogram

Planned output

Energy fluence

MVCT image

Reconstructed dose

Figure 5. Block diagram of DV and DR for TomoTherapy
1.5

Hypothesis and Specific Aims
1.5.1

Hypothesis

Comparison of measured and reconstructed doses (based on TomoTherapy DVPA
software) for head and neck, prostate and lung plans delivered to the TomoPhantom with and
without intentional delivery errors will demonstrate:
(a) agreement within 2% for a point in a high dose, low gradient region
(b) a gamma index < 1 for 90% of the points within a selected two dimensional region
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1.5.2

Specific Aims

1. Create three different TomoTherapy treatment plans on the TomoPhantom. Generate plans
using PTV and OAR contours extracted from clinical treatment plans for a head & neck
(H&N), prostate and lung, and placed on the TomoPhantom. Optimize plans using standard
clinical protocols.
2. Deliver, measure and extract the exit detector data for each plan
a. multiple times on different days (to account for statistical fluctuation)
b. with intentional adjustment to machine’s output
c. with intentional leaf opening time error (to determine the significance of leaf opening
time error within the set tolerance of the delivery system)
3. Compute the reconstructed dose on DVPA software using the treatment detector sinogram.
4. Compare the measured dose with the original planned dose and the reconstructed dose
calculated. Compare both point dose (ion chamber) and relative dose (film) results.
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CHAPTER 2. METHODS AND MATERIALS
2.1

Aim 1: Generate Treatment Plans
2.1.1

TomoTherapy TomoPhantom

Plans for this study were generated on the TomoTherapy-provided cylindrical
measurement phantom, or TomoPhantomTM (TomoTherapy Inc.) (Figure 6). The two halves of
the TomoPhantom combine to create a cylinder with dimensions of 30 cm in diameter and 18 cm
in length. The material of the homogeneous phantom consists of Virtual WaterTM with a density
of 1.024 gram per cm3.19 Along one diameter on the side of the phantom, there are 28 6.3-mm
diameter cylindrical slots aligned parallel to the cylinder axis and separated by 1 cm from their
centers to allow for point dose measurements using ionization chambers (Figure 7). There are
virtual water plugs for the slots that don’t have a detector. Relative dose distribution
measurements may be achieved by placing a radiographic film between the 2 halves of the
phantom.

Figure 6. Photo of the TomoPhantom with the two halves apart
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Holes start 1 cm
above center

15 cm

Holes start 0.5 cm
below center
18 cm
Figure 7. Axial and sagittal (central cut) view of the TomoPhantom
2.1.2

Scanning and Transferring the Image of the TomoPhantom

The TomoPhantom was scanned on the GE Lightspeed RT CT scanner available at Mary
Bird Perkins Cancer Center. Orientation of the phantom was set such that the circular volume is
in the axial plane with the cylindrical slots lined up vertically during scan. The scanning
parameters were set as the following:
•
•
•
•
•
•

Helical scan
50 cm diameter field of view
512×512 axial pixel resolution
2.5 mm longitudinal spacing
83 slices = 20.75 cm
120 kVp beam energy

After obtaining an image dataset of the TomoPhantom, the same image dataset was sent
to the TomoTherapy Research TPS three separate times to create three different treatment plans.
Each time, the name of the image dataset was changed to create and identify the three different
plans (“DV STUDY – H/N”, “DV STUDY – PROSTATE” and “DV STUDY – LUNG”).
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The image dataset was also sent once to Pinnacle3 TPS for the purpose of creating a
structure set for each plan. Since the phantom is not anthropomorphic, a virtual structure set for
each plan was obtained by copying a patient’s structure set with disease sites corresponding to
those studied here. Figures 8 and 9 illustrate the copying of contours from a patient plan to the
TomoPhantom for the lung case. Figure 8 shows axial, coronal and sagittal slices through a
patient’s CT dataset. The target volume and critical structures have been contoured and are
displayed by colored lines on the CT images. The structure sets was copied to the phantom
image dataset as seen in Figure 9.
Axial

Coronal

Sagittal

Figure 8. Contours of lung patient with target volume in red
Axial

Coronal

Figure 9. Contours of lung patient copied onto the TomoPhantom
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Sagittal

2.1.3

Treatment Planning

Copying of the contours for each plan in Pinnacle3 TPS required adding a patient image
dataset corresponding to the disease site into the plan’s list of images. The patient’s image
dataset was set as the secondary image while the TomoPhantom image dataset was set as the
primary image. Importing of the patient’s structure set was done separately within each plan and
was assigned to the patient’s image dataset initially. The patient’s image dataset (with the
structure set) was then fused with the TomoPhantom image dataset. This allowed displaying and
shifting of the structure set position relative to the TomoPhantom. The structure set was shifted
such that the center of the target volume covered the active measurement volume of the
ionization chamber (see Figure 9). The structure set was then assigned to the TomoPhantom’s
image dataset and exported to the TomoTherapy Research TPS.
Image data that were imported into TomoTherapy Research TPS were down-sampled to
256×256 axial pixel resolution. Planning parameters (jaw size setting, pitch, prescription dose
on PTVs and dose tolerances for OARs) for each plan used standard clinical protocols in use at
MBPCC and are shown in Table 1. Treatment delivery was set to 2 Gy per fraction to simulate
patient treatment. Figure 10 shows an overview for the generation of the plans.
TomoPhantom image dataset
Pinnacle3 TPS

TomoTherapy Research TPS

copied contours from patient plans

generated plans

H &N

H &N

Prostate

Prostate

Lung

Lung

Figure 10. Block diagram showing how the treatment plans were created.
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Table 1.

Planning parameters and dose tolerance [dose @ % volume] for critical
structures

Plans were optimized using beamlet mode with a modulation factor of 3.0 and 4.0 (see
Table 1). Settings for the importance of PTV were initially set 3 times more than the avoidance
structures. Penalties for all structures were initially set to 1. The procedure used for adjusting
penalties during optimization followed the standard recommended procedure from
TomoTherapy. Changes in penalties were made after every 12 iterations and to only those
structures that did not yet meet the plan objectives as outline in Table 1. The total number of
iterations for each plan had approximately 120 iterations. Although the plan quality was not of
interest for this study, the final plans were made to resemble typical clinical plans. Each plan
was then archived and transferred onto the delivery system data server for delivery.
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2.2

Aim 2: Delivery of Treatment Plans
2.2.1 Measurement Setup
Prior to the delivery of each plan, an MVCT scan was taken of the TomoPhantom to

verify and adjust alignment, if necessary. To prevent exposure to the film before the planned
delivery, no film was placed in the phantom during scan. Measurements were collected using an
ionization chamber (Model A1SL Exradin Miniature Shonka Thimble Chamber), with a
collecting volume of 0.057 cm3, placed in one of the cylindrical slots of the TomoPhantom and
an Extended Dose Range 2 (EDR2) radiographic Kodak film placed in between the two halves of
the phantom (Figure 11). The electrometer (Keithley Model 614) used to take readings from the
ionization chamber had a bias voltage setting of -300V with a maximum leakage rate of 0.01
nC/minute.
The prostate and lung plans were delivered with the phantom orientation as seen in
Figure 10a. For the H&N plan, the phantom was rotated 90° counterclockwise (Figure 10b) so
that the ionization chamber could be within the plan’s PTV.

(a)

(b)

Figure 11. Film measurement in the (a) coronal plane and (b) sagittal plane
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2.2.2 Treatment Delivery
Each plan was delivered twice per day and repeated over several days to account for
statistical fluctuations. For each delivery, measurements for each plan consisted of two ion
chamber readings and one film exposure. The temperature and pressure were recorded at the
time of measurements to correct for the ion chamber calibration value (PTP).
Conversion of the ion chamber’s electrometer reading (Mraw) to measured dose (DM)
followed the AAPM TG-51 protocol20 given by equation 2.
   



     

Pion:

ion recombination correction

PTP:

temperature & pressure correction

Pelec:

electrometer calibration factor [C/reading]

Ppol:

chamber polarity effects

kQ:

beam quality conversion factor

(2)



 : ionization chamber calibration factor [Gy/C]
Values of Pion (1.004) and Ppol (1.000) had previously been determined for this chamber
following TG-51 protocol. The value of kQ (0.996) was obtained using the procedure


recommended by Thomas et al.21 The calibration factor for both the ionization chamber ( )
and the electrometer (Pelec) had been obtained within the past 2 years from an Accredited
Dosimetry Calibration Laboratory (ADCL).
A calibration film was exposed on each day that measurements were made in order to
convert the chemical response due to radiation exposure of the film to the dose deposited. The
calibration film consists of 8 rectangular regions that were exposed to a range of radiation
exposures (Figure 12a)22 from a Varian 21EX linear accelerator using the same nominal beam
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energy (6 MV) as the TomoTherapy Hi·Art delivery system. The calibration film was placed at
100 cm source-to-axis distance with 10 cm of buildup and 5 cm of backscatter using a Plastic
Water phantom® (Computerized Imaging Reference Systems Inc., 2428 Almeda Ave. Suite 316,
Norfolk, VA 23513). A typical calibration curve is shown in Figure 12b.
35000
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(a)

(b)

Figure 12. (a) Scanned image of calibration film after exposure and processing and
(b) a typical calibration curve
The average optical density value within a small rectangular region (~3×3 cm) for each of
the exposed area was obtained from the scanned image. Dose delivered to the exposed area
corresponds to a measured dose that had been made using an ionization chamber placed within
the same region under the same setup. All exposed films were processed 24 hours after delivery
(due to variations in dose response within 1 hour of exposure)23 and were scanned using a Vidar
DosimetryPro Advantage film digitizer (VIDAR Systems Corporation, 365 Herndon Parkway,
Herndon, VA 20170). The films were scanned with a resolution of 71 pixels per inch at 16 bit.
In addition to the standard treatment deliveries, each plan was delivered with the output
or leaf open times intentionally adjusted away from their baseline value. Adjustments in output
were made by varying the voltage setting of the pulse forming network (pfn) at the treatment
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console prior to delivery. Pfn voltage settings were adjusted to vary the output by approximately
0.5 - 4% per delivery in either directions. Output variations of more than 4% will trigger an
interlock and stop the delivery.
Adjustments in leaf open times were made by modifying the leaf control sinogram files.
A separate leaf control sinogram file is created for every scheduled treatment and is accessible in
a patient plan archive. In each patient’s archive folder, unique identifiers (UID) are given to
most of the filenames in the archive directory (e.g., “1.2.826.01.3680043.2.200.2136569166.142.83541.763.sin”). All UIDs are indexed within a single plan’s extensible markup language
(xml) file, which is also located under the archive directory. The xml file for each plan was
opened using a text editor program (e.g., Notepad). Within the xml file, the leaf control
sinogram files UID were listed next to the tag “sinogramDataFile” associated with each date of
planned treatment delivery. These numbers were recorded in order to access the sinogram files
for this study.
For each patient plan, twelve leaf control sinogram files were modified. A tracking
record was kept that associated the modified file with the scheduled delivery date. The file
contained a matrix of Nproj by 64 floating point numbers ranging in value from 0 to 1.0, where
Nproj is the number of projections for the treatment. These data represent the fraction of time the
leaves remain open for each projection. The sinogram files were written in binary (little-endian)
format and were read and byte swapped using a software program called “Transform” (version
3.4, Fortner Software LLC). The matrix data were then copied onto an Excel spreadsheet to
modify the leaf open times.
The time equivalent (∆t) for each matrix value was determined by multiplying the value
by the projection period (equation 3). The projection period was determined by dividing the
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gantry period (given on the plan printout) by the number of projections per rotation (stated
previously as 51).
&'!()*+
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The modified matrix data were byte swapped using in-house software, and then copied
back onto the Transform program to save it with the proper file name extension. With the
modified leaf control sinogram files placed within the archived directory, the plans were
retrieved back into the database of the TPS to allow for plan deliveries on the Hi·Art delivery
system.
The TomoTherapy Hi·Art delivery system gives a fault and stops treatment when leaf
open time errors of ≥ 32 milliseconds (msec) for 4 instances are detected. Intentional leaf open
time errors were introduced which were close to but within these limits, in order to test the limits
of the correction software. The leaf open times were adjusted for all the leaves by approximately
±10 and ±30 msec (actual adjustment time is dependent on the value from equation 3). Then
only the center leaf (since most tomotherapy treatments position the target at isocenter) or the
leaf that contributes the most to the target was adjusted by approximately ±10 and ±30 msec to
determine the effect on dose delivery. For modified leaf open time values that are greater than
1.0 or less than 0.0, we set them to 1.0 or 0.0 since values outside the range of 0 and 1 are not
deliverable.
2.3

Aim 3: Dose Reconstruction Using Detector Data
Treatment delivery data were immediately extracted after each delivery, since these data

were erased whenever a new procedure was loaded for delivery. The detector data contain signal
information from the centrally located 640 (out of 738) xenon exit detectors and the three
monitor chambers located between the x-ray source and MLC (Figure 13). The data was
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acquired for every pulse of the linac, which operates at a frequency of 300 pulses per second in
treatment mode.
Source
Monitor Chambers
MLC

Patient
Couch

Exit Detectors

Figure 13. Locations of monitor chambers and exit detectors
The extracted detector data files were transferred to the TomoTherapy Research TPS.
These data were read in by the DVPA software to determine the DV sinogram based on
variations in machine output and/or leaf open times during treatment delivery. The DVPA
software is capable of creating a DV sinogram by considering either factor individually or
combined.
As described in section 1.4.2, the DVPA software scales each measured leaf open time by
the percent difference between measured and planned beam output over the period of the
projection. At the time of the initial beam commissioning, output was adjusted to deliver 900
cGy per minute for a static beam of 40 × 6 cm field size, to a depth of 1.5 cm at the isocenter of
the machine. After this adjustment was complete, the average digital signal/pulse of each
monitor chamber (MU1) was stored on the DVPA software. The current value for MU1 on the
system at Mary Bird Perkins is 16003 counts per pulse. For each leaf, the planned beam output
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at any projection is found by multiplying this value by the number of pulses the leaf was opened.
The measured output is obtained by summing the counts from MU1 over the same pulses.
If variations in leaf open time relative to the planned treatment are considered in
determining the DV sinogram, then the FWHM of the exit detector array signal is used to
determine the actual leaf open time. At 300 pulses per second, the time between pulses is
approximately 3 msec, which is small compared to typical leaf open times of 200 msec from
planned treatment deliveries studied in this work.
Figures 14a, 14b and 15 are screenshots from the DVPA software program which display
sample DV sinograms using each factor individually and the combined factors, respectively.
The three sinograms represents partial view of the leaf control sinogram for the planned,
reconstructed (DV sinogram) and their difference. The horizontal axis is the leaf number and the
vertical axis is the projection number. Each cycle in the sinogram represents one rotation of the
gantry. Each point in the sinogram matrix represents leaf open time for a specific leaf in unit of
second with the brighter colors having longer open times (red being the longest and black
meaning closed leaf). The machine output during delivery, determined from the monitor
chamber data, is shown as the oscillating purple line.
For all three figures, locations of the crosshair are the same to show how DVPA account
variations in machine output and leaf open time separately and their combined contribution to the
final DV sinogram. The verification histogram on the right side of Figures 14 and 15 shows the
leaf open time differences for fraction of active leaf states. Notice how variations in leaf open
time contribute to differences between the planned and reconstructed sinograms more so than
machine output variations.
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(a)

(b)
Figure 14. Comparison of the planned sinogram and reconstructed sinogram based on
(a) machine output and (b) leaf opening time.
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Figure 15. Comparison of the planned sinogram and reconstructed sinogram based on
both leaf opening time and machine output.
DR in the DVPA software is computed based on a leaf control sinogram and an image
dataset. For leaf control sinogram, DVPA allows the option to either use the planned or DV
sinogram. For the image dataset, DVPA allows the option to either use the planned/reference
image dataset or to use an MVCT image dataset taken immediately prior to treatment. If an
MVCT image dataset is chosen, then a different IVDT is required, since the relationship between
CT number and density is changed. Although this is beneficial for a patient with daily setup
changes, it is not required for a phantom. Therefore, all reconstructed doses for this study were
computed using the reference image and the corresponding DV sinogram with the dose grid set
to fine. The reference image dataset was chosen over the MVCT image dataset to omit any
density differences, therefore, image dependency on the reconstructed dose relative to the
planned dose.
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To confirm that the dose algorithm in DVPA is the same as the TPS, a DR was computed
on the unmodified H&N plan using the reference image and the planned sinogram. The result
showed that there was no difference in the dose distribution between the planned and
reconstructed.
2.4

Aim 4: Dose Comparison of Measurements Versus Reconstructed
After DVPA dose reconstruction calculations were performed, the calculated point doses

(at the location of the ion chamber) and the planar dose distributions (at the location of the film
plane) were extracted from the system for comparison with measurement results. These
comparisons were made using the quality assurance tools available on the DVPA software and
on the planning station application on the TomoTherapy Research TPS.
The calculated point doses used in comparing with the measured data were chosen to be
at the center of the ion chamber’s active volume. The dose grid point in the calculated dose
matrix closest to this location was selected. In the DVPA software, point dose values from the
planned and reconstructed dose distributions are displayed to the thousandth decimal and are in
units of gray.
Standard deviations for both the measured and calculated point doses were determined
using equation 4. If both the measured or calculated dose for each scheduled delivery have the
exact same value, then the standard deviation was set to half of the last significant digit (e.g.,
2.07 Gy will have σ = ±0.005).
L
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(4)

Calculation for the differences between measured and reconstructed doses used equation
5. The sum of their standard deviations is taken as the square root of the sum of their square
(equation 6).
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Evaluation of the film measurements were done within the TomoTherapy Research TPS.
It provides a Delivery Quality Assurance (DQA) analysis tool where the DQA plan and
measured dose distributions are overlaid for comparisons in one dimension (dose profiles) and/or
two dimensions (isodose or gamma index distributions). The DQA plan simulates the planned
treatment on a measurement phantom for dose delivery verification. Dose in the DQA plan
contains the composite dose from all treatment fractions. In order to compare film
measurements with the reconstructed dose distributions computed by DVPA, a DQA plan was
created for each patient plan. The dose file created in the DQA plan was then replaced with a
reconstructed dose file.
Reconstructed dose files have an “.img” filename extension and are the same dimension
and file size as the planned and DQA dose files. All dose files are accessible under the patient
archive directory. Identifying a reconstructed dose file to the corresponding treatment delivery
was done by associating the date and time it was computed on the DVPA planning system to the
date and time that is associated with a filename within the xml file. The same was done for the
DQA dose file.
Before replacing the DQA dose file with a reconstructed dose file, each reconstructed
dose was scaled up by a factor equal to the total number of fractions for the planned treatment.
This is due to the fact that the DQA analysis tool scales the calculated dose down to one fraction
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for comparison with the measured data (film), which were measured from a single fraction
delivery. Replacement of the DQA dose file with the reconstructed dose file was made by
renaming the reconstructed dose file to the DQA’s filename. The archive was then retrieved
back into the TomoTherapy Research TPS. This step was repeated for every reconstructed dose
used to compare with the corresponding measured film data.
Film dosimetry evaluation for this study uses a technique that gives a quantitative
analysis of the dose distributions between measured and computed data, also known as gamma
index distibution.24 This technique is a composition of two types of comparisons: 1) dose
difference in regions of low dose gradient and 2) distance-to-agreement (DTA) in region of high
dose gradients. The latter is used because small spatial error in high dose gradient regions could
result in large dose difference. Determination of a pass or fail gamma index is dependent on the
conditions set in the parameters for dose difference and DTA tolerances. Independent of the
conditions, a gamma index of ≤ 1 is considered passing using equation 7. Figure 16 is a
graphical illustration of the gamma index that visually defines the variables used in equations 7
and 8. The surface of the elliptical sphere, which is dependent on the values of the dose
difference and the DTA tolerances, represents a gamma value of 1.
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Figure 16. Graphical illustration of the gamma index distribution
This study uses TomoTherapy Planning Station Alpha6, which provides a histogram of
the gamma index within a selected region of interest. A maximum region of interest was chosen
while keeping the borders at least 2 cm from the phantom edges to avoid markings on the edge of
the film used for registration. The regions selected for all film analysis of the same study were
consistent to within 0.5 mm (see Figure 17). The standard conditions used for the gamma index
were: dM = 3 mm, DM = 3% of max dose.
Analysis of film measurements were made after scaling the film dose distributions based
on the ionization chamber measurements. It was assumed that the ratio of doses to an arbitrary
point on the film (Dfilm) to the ion chamber (Dic) should be the same for the measurement (m) and
the reconstructed (r) plan. The film point was selected to be in a low dose gradient region, as
close as possible to the ion chamber point. The film dose was scaled by the following scaling
factor:
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Figure 17. Displays a screenshot of the film analysis program of the
TomoTherapy TPS. Shown are isodose lines from computed (solid)
and measured (dash) dose distributions overlaid on a reconstructed
coronal slice of the measurement phantom. The yellow rectangle
shows the ROI selected for this study.
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CHAPTER 3. RESULTS AND DISCUSSION
3.1

Aim 1: Generate Treatment Plans
Contours for each of the three plans were copied from a patient plan that corresponded to

their treatment site. Treatment planning parameters were set to simulate typical patient plans
using standard clinical protocols in use at MBPCC. Figures 18, 20 and 22 show the optimized
dose distributions from three different views (axial, coronal and sagittal) of the H&N, prostate
and lung plans, respectively. Figures 19, 21 and 23 show the dose volume histograms (DVH) of
the H&N, prostate and lung plans, respectively. Despite being optimized on a cylindrical
phantom, the dose distributions for each plan are similar to clinical plan results. Dose within the
PTVs have a high dose/low gradient which help reduce errors associated with misalignment of
ionization chamber during measurements. Dose to the critical structures for the three plans are
below standard clinical tolerances.
Since all plans simulated those of clinical patient plans, parameters which affect delivery
errors (gantry rotational speed, couch speed and leaf opening time) are likely to be close to
clinical values. All plans were also fractionated so that each treatment delivery will deliver a
dose of 2 Gy to the PTV.
Axial

Coronal

Sagittal

Figure 18. Dose distribution (isodose values are in Gy) of the H&N plan
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Brain

PTV
Lt Parotid

Cord

Figure 19. DVH of the H&N plan
Axial

Coronal

Sagittal

Figure 20. Dose distribution of the prostate plan

PTV
Bladder

Rectum

Figure 21. DVH of the prostate plan
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Axial

Coronal

Sagittal

Figure 22. Dose distribution of the lung plan

PTV
Lung
Cord

Figure 23. DVH of the lung plan
3.2

Aim 2: Delivery and Measurements of Treatment Plans
Measured data from the delivery of the H&N, prostate and lung plans are shown in

Tables 2, 3 and 4, respectively. Film data are not shown here but will be discuss in section 3.4.2.
The planned dose at the point of measurement for the H&N, prostate and lung plans are 2.037
Gy, 2.063 Gy and 2.022 Gy, respectively. Each delivery procedure was measured twice per day
and is separated in the tables by highlights. Temperature and pressure readings were taken at the
end of each delivery. The calibration factors of the electrometer and ion chamber were also
recorded. Deliveries made without intentional changes to the planned are labeled ‘Normal’.
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Deliveries made with intentional offsets to the output are labeled as ‘∆pfn’ along with the
voltage difference from the machine’s current value. Calculations for the measured dose used
Equation 2 (c.f., section 2.2.2).

Table 2.

Ion chamber measurements for the H&N plan (planned dose = 2.037 Gy)

Delivered Plan
(H&N)
Normal - Day 1
Normal - Day 1
Normal - Day 2
Normal - Day 2
Normal - Day 3
Normal - Day 3
Normal - Day 4
Normal - Day 4
Normal - Day 5
Normal - Day 5
Normal - Day 6
Normal - Day 6
Normal - Day 7
Normal - Day 7
All leaves -10 ms
All leaves -10 ms
All leaves +10 ms
All leaves +10 ms
All leaves -30 ms
All leaves -30 ms
All leaves +30 ms
All leaves +30 ms
Leaf #27 -10 ms
Leaf #27 -10 ms
Leaf #27 +10 ms
Leaf #27 +10 ms
Leaf #33 -10 ms
Leaf #33 -10 ms
Leaf #33 +10 ms
Leaf #33 +10 ms

Reading
0.384
0.383
0.380
0.380
0.383
0.383
0.381
0.381
0.378
0.379
0.368
0.369
0.372
0.372
0.351
0.350
0.410
0.410
0.296
0.295
0.449
0.451
0.381
0.381
0.384
0.384
0.382
0.382
0.384
0.384

Temp.
(°C)
23.8
23.8
23.9
23.9
23.4
23.4
23.3
23.3
23.9
24.1
24.1
24.0
24.6
25.0
23.9
23.9
24.4
24.4
24.3
24.8
24.8
24.6
24.5
24.5
24.6
24.6
24.6
24.6
24.6
24.6

Pressure
[mmHg]
765.0
765.0
763.0
763.0
756.3
756.3
769.5
769.5
770.0
770.0
761.0
761.0
763.0
763.0
763.0
763.0
763.0
763.0
763.0
763.0
763.0
763.0
763.0
763.0
762.0
762.0
762.0
762.0
761.0
761.0

Electrometer
Cal. [C/Rdg]
9.87E-09
9.87E-09
9.87E-09
9.87E-09
9.87E-09
9.87E-09
9.87E-09
9.87E-09
9.87E-09
9.87E-09
1.004E-08
1.004E-08
1.004E-08
1.004E-08
9.87E-09
9.87E-09
9.87E-09
9.87E-09
1.004E-08
1.004E-08
1.004E-08
1.004E-08
9.87E-09
9.87E-09
9.87E-09
9.87E-09
9.87E-09
9.87E-09
9.87E-09
9.87E-09
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Chamber
Cal. [Gy/C]
5.468E+08
5.468E+08
5.468E+08
5.468E+08
5.468E+08
5.468E+08
5.468E+08
5.468E+08
5.468E+08
5.468E+08
5.468E+08
5.468E+08
5.468E+08
5.468E+08
5.468E+08
5.468E+08
5.468E+08
5.468E+08
5.468E+08
5.468E+08
5.468E+08
5.468E+08
5.468E+08
5.468E+08
5.468E+08
5.468E+08
5.468E+08
5.468E+08
5.468E+08
5.468E+08

Measured
Dose [Gy]
2.071
2.066
2.056
2.056
2.087
2.087
2.040
2.040
2.027
2.033
2.032
2.037
2.052
2.055
1.899
1.894
2.222
2.222
1.631
1.628
2.479
2.488
2.065
2.065
2.085
2.085
2.070
2.070
2.088
2.088

Table 3.

Ion chamber measurements for the prostate plan (planned dose = 2.063 Gy)

Delivered Plan
(Prostate)
Normal - Day 1
Normal - Day 1
Normal - Day 2
Normal - Day 2
Normal - Day 3
Normal - Day 3
Normal - Day 4
Normal - Day 4
Normal - Day 5
Normal - Day 5
Normal - Day 6
Normal - Day 7
Normal - Day 7
Normal - Day 7
All leaves -10 ms
All leaves -10 ms
All leaves +10 ms
All leaves +10 ms
All leaves -30 ms
All leaves -30 ms
All leaves +30 ms
All leaves +30 ms
Leaf #33 -10 ms
Leaf #33 -10 ms
Leaf #33 +10 ms
Leaf #33 +10 ms
Leaf #33 -30 ms
Leaf #33 -30 ms
Leaf #33 +30 ms
Leaf #33 +30 ms
∆pfn: +0.01 V
∆pfn: +0.01 V
∆pfn: +0.02 V
∆pfn: +0.04 V
∆pfn: +0.07 V
∆pfn: +0.07 V
∆pfn: -0.07 V
∆pfn: -0.07 V

Reading
0.380
0.380
0.379
0.378
0.378
0.378
0.375
0.375
0.380
0.380
0.371
0.370
0.373
0.373
0.352
0.352
0.406
0.406
0.294
0.294
0.458
0.458
0.367
0.368
0.386
0.383
0.350
0.350
0.406
0.406
0.383
0.383
0.385
0.389
0.388
0.389
0.356
0.354

Temp.
(°C)
23.5
23.8
23.7
23.8
24.3
24.5
24.1
24.2
24.5
24.5
24.0
24.2
23.6
23.8
24.0
23.8
23.8
23.8
23.8
23.9
23.9
23.9
24.3
24.3
24.3
24.8
24.5
24.5
24.7
24.7
24.4
24.4
24.5
24.5
23.9
24.2
23.9
24.2

Pressure
[mmHg]
761.0
761.0
758.0
758.0
755.0
755.0
754.5
754.5
761.0
761.0
761.0
761.0
762.0
762.0
761.0
761.0
761.0
761.0
758.0
758.0
758.0
757.5
755.0
755.0
755.0
755.0
761.0
761.0
761.0
761.0
762.0
762.0
761.5
761.5
761.0
761.0
761.0
761.0

Electrometer
Cal. [C/Rdg]
9.87E-09
9.87E-09
9.87E-09
9.87E-09
9.87E-09
9.87E-09
9.87E-09
9.87E-09
9.87E-09
9.87E-09
1.004E-08
1.004E-08
1.004E-08
1.004E-08
9.87E-09
9.87E-09
9.87E-09
9.87E-09
9.87E-09
9.87E-09
9.87E-09
9.87E-09
9.87E-09
9.87E-09
9.87E-09
9.87E-09
9.87E-09
9.87E-09
9.87E-09
9.87E-09
9.87E-09
9.87E-09
9.87E-09
9.87E-09
1.004E-08
1.004E-08
1.004E-08
1.004E-08
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Chamber
Cal. [Gy/C]
5.468E+08
5.468E+08
5.468E+08
5.468E+08
5.468E+08
5.468E+08
5.468E+08
5.468E+08
5.468E+08
5.468E+08
5.468E+08
5.468E+08
5.468E+08
5.468E+08
5.468E+08
5.468E+08
5.468E+08
5.468E+08
5.468E+08
5.468E+08
5.468E+08
5.468E+08
5.468E+08
5.468E+08
5.468E+08
5.468E+08
5.468E+08
5.468E+08
5.468E+08
5.468E+08
5.468E+08
5.468E+08
5.468E+08
5.468E+08
5.468E+08
5.468E+08
5.468E+08
5.468E+08

Measured
Dose [Gy]
2.059
2.061
2.063
2.059
2.070
2.071
2.050
2.051
2.065
2.065
2.048
2.044
2.053
2.055
1.908
1.908
2.202
2.202
1.601
1.601
2.494
2.508
2.009
2.015
2.113
2.102
1.902
1.902
2.208
2.208
2.078
2.078
2.091
2.113
2.141
2.149
1.964
1.955

Table 4.

Ion chamber measurements for the lung plan (planned dose = 2.022 Gy)

Delivered Plan
(Lung)
Normal - Day 1
Normal - Day 1
Normal - Day 2
Normal - Day 2
Normal - Day 3
Normal - Day 3
Normal - Day 4
Normal - Day 4
Normal - Day 5
Normal - Day 5
All leaves -10ms
All leaves -10ms
All leaves +10 ms
All leaves +10 ms
All leaves -30 ms
All leaves -30 ms
All leaves +30 ms
All leaves +30 ms
Leaf #32/33 -10 ms
Leaf #32/33 -10 ms
Leaf #32/33 +10 ms
Leaf #32/33 +10 ms
Leaf #32/33 -30 ms
Leaf #32/33 -30 ms
Leaf #32/33 +30 ms
Leaf #32/33 +30 ms
∆pfn: -0.05 V
∆pfn: -0.05 V
∆pfn: +0.05 V
∆pfn: +0.05 V
∆pfn: -0.07 V
∆pfn: -0.07 V
∆pfn: +0.07 V
∆pfn: +0.07 V

Reading
0.363
0.364
0.363
0.363
0.357
0.357
0.358
0.358
0.353
0.353
0.339
0.339
0.389
0.389
0.289
0.289
0.439
0.439
0.343
0.343
0.384
0.384
0.299
0.298
0.429
0.428
0.351
0.350
0.373
0.373
0.340
0.341
0.374
0.373

Temp.
(°C)
24.4
24.4
23.6
24.3
23.8
23.7
23.8
23.8
24.6
24.8
24.6
24.6
24.8
24.8
24.8
24.8
24.8
24.8
24.2
24.2
24.3
24.2
24.3
24.3
24.4
24.2
24.3
24.3
24.0
24.2
24.3
23.9
24.1
24.1

Pressure
[mmHg]
761.0
761.0
761.0
761.0
761.0
761.0
762.0
762.0
762.0
762.0
761.0
761.0
761.0
761.0
762.0
762.0
762.0
762.0
761.0
760.5
760.0
760.0
760.0
760.0
760.0
760.0
760.0
760.0
760.0
760.0
761.0
761.0
761.0
761.0

Electrometer
Cal. [C/Rdg]
9.87E-09
9.87E-09
9.87E-09
9.87E-09
1.004E-08
1.004E-08
1.004E-08
1.004E-08
1.004E-08
1.004E-08
9.87E-09
9.87E-09
9.87E-09
9.87E-09
9.87E-09
9.87E-09
9.87E-09
9.87E-09
9.87E-09
9.87E-09
9.87E-09
9.87E-09
9.87E-09
9.87E-09
9.87E-09
9.87E-09
9.87E-09
9.87E-09
9.87E-09
9.87E-09
1.004E-08
1.004E-08
1.004E-08
1.004E-08

Chamber
Cal. [Gy/C]
5.468E+08
5.468E+08
5.468E+08
5.468E+08
5.468E+08
5.468E+08
5.468E+08
5.468E+08
5.468E+08
5.468E+08
5.468E+08
5.468E+08
5.468E+08
5.468E+08
5.468E+08
5.468E+08
5.468E+08
5.468E+08
5.468E+08
5.468E+08
5.468E+08
5.468E+08
5.468E+08
5.468E+08
5.468E+08
5.468E+08
5.468E+08
5.468E+08
5.468E+08
5.468E+08
5.468E+08
5.468E+08
5.468E+08
5.468E+08

Measured
Dose [Gy]
1.972
1.978
1.967
1.972
1.969
1.969
1.972
1.972
1.950
1.951
1.843
1.843
2.117
2.117
1.570
1.570
2.385
2.385
1.862
1.864
2.089
2.088
1.626
1.621
2.334
2.327
1.909
1.904
2.027
2.028
1.879
1.882
2.065
2.060

The measurement results in Tables 2-4 show a wide range of point doses measured near
the center of the target volume of each plan. The top portion of each table displays results for
treatment plans delivered without any intentional variation in output or leaf open time. In
general, these data show little to no variation between doses measured on the same day, although
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small differences are seen between doses measured on different days. The minimum and
maximum measured doses ranged from (2.03, 2.09) Gy, or (-0.3%, +2.6%) of the planned dose,
for the H&N plan; (2.05, 2.07) Gy, or (-0.6%, +0.3%) for the prostate plan, and (1.95, 1.98) Gy,
or (-3.6%, -2.1%) for the lung plan. The lung plan had the worst agreement when comparing
with the planned dose, although the overall agreement was still within 4%.
The measurement results for leaf open time changes in Tables 2-4 show the largest
variation in doses from the planned doses. Results are displayed for a constant increase in all
leaf open times for all projections for both an individual leaf, and all 64 leaves. As expected, the
differences were largest when all leaf open times were intentionally adjusted by 30 msec. The
variation seen for these cases were (-20.0%, +22.2%) for H&N plan, (-22.4%, +21.2%) for the
prostate plan, and (-22.4%, +18.2%) for the lung plan.
The magnitude of the changes for the adjustment of one or two leaf open times varied
according to treatment plan. For the H&N plan, where either leaf number 27 or 33 were
adjusted, the measured doses ranged from (2.07, 2.09) Gy, or (+1.6%, +2.6%) above the plan
dose. For the prostate plan, a larger variation was seen when leaf number 33 was adjusted by the
same amount, with measured doses ranging from (2.01, 2.11) Gy, or (-2.6%, +2.3%) above the
plan dose. This difference may be due to the fact that the H&N target and measurement point
are located further away from the tomotherapy axis or rotation, so that individual leaves
contribute to the dose at this point for a few projections only. In the H&N case, the measurement
was made 4 cm from the axis, while the lung and prostate doses were measured 0.5 cm from the
axis. For the lung plan, the two leaves centered on the central axis (number 32 and 33) were
varied by both 10 and 30 msec. In this case the variation in measured dose was larger, ranging
from (1.86, 2.09) Gy, or (-8.0%, +3.4%).
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The intentional changes made to the leaf open times were much larger than those seen in
a typical treatment delivery (c.f., Figure 14 from Chapter 2). Nevertheless, these changes test the
accuracy of the DVPA program under extreme conditions.
Linac output rates were adjusted for both the lung and prostate treatment deliveries by
adjusting the pfn voltage up to ±0.07 volts. These results are also displayed in Tables 3 and 4.
In these cases, the measured doses scaled proportional to the pfn voltage, with a slope of
approximately 0.65% per unit change in pfn (1 cV). Larger changes in pfn voltage setting (i.e.,
±0.08 volts) resulted in the machine interlock.
3.3

Aim 3: Dose Reconstruction Using Detector Data
3.3.1

H&N Plan

Reconstructed doses computed on DVPA use the DV sinogram and the reference image.
Figures 24a, 24b and 24c shows the reconstructed (dashed) and planned (solid) isodose lines of
the H&N study for the planned, +10 msec offset to center leaf and +10 msec offset to all leaves
deliveries, respectively. Figures 25a, 25b and 25c are the corresponding DVHs. As expected,
the reconstructed dose from planned delivery of the H&N study matched well with the planned
dose (Figures 24a and 25a). However, a slight difference in the dose delivered (~2%) is seen in
Figures 24b and 25b due to placing a +10 msec offset to the center leaf for the entire delivery.
The reconstructed isodose lines cover a larger volume relative to the planned isodose lines.
Adjusting all leaves by +10 msec caused a larger increase in the dose delivered by approximately
8% (Figures 24c and 25c).
Note that Figures 24-25 displays only a portion of the delivered plans made in this study
to illustrate the effect of leaf open time errors in the delivered dose.
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Axial

Sagittal

(a)

(b)

(c)

Figure 24. Isodose [Gy] overlay of the planned (solid) and reconstructed (dashed) for
(a) planned delivery, (b) +10 msec offset to center leaf delivery and (c) +10
msec offset to all leaves delivery from the H&N study
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(a)

(b)

(c)

Figure 25. DVH comparison between the planned (solid) and reconstructed (dashed)
for (a) planned delivery, (b) +10 msec offset to center leaf delivery and
(c) +10 msec offset to all leaves delivery from the H&N study
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3.3.2

Prostate Plan

For the prostate study, isodose lines of a reconstructed dose from a planned delivery
matched the planned isodose lines (Figure 26a) with their DVHs showing no significant
difference (Figure 27a). The delivery with an intentional offset to the center leaf by +30 msec
led to an overdose along the central axis of the phantom which is depicted in Figure 26b. Figure
27b displays the corresponding PTV, which was located about the central axis of the machine,
receiving an overdose for a portion of its volume. Delivery with a +30 msec offset to all leaves
caused an increase in the overall dose delivered by approximately +20% (Figures 26c and 27c).
Delivery with a machine output offset of 0.7 V to the pfn (approx. +3.9%) yield to a delivered
dose of approximately +4% (Figures 26d and 27d), as expected.
Not all reconstructed doses for the prostate plan are shown, but the results for each agreed
accordingly with the different offsets applied to the delivery.

Axial

Sagittal

(a)

Figure 26. Isodose [Gy] overlay of the planned (solid) and reconstructed (dashed) for
(a) planned delivery, (b) +30 msec offset to center leaf delivery, (c) +30
msec offset to all leaves delivery and (d) +0.7 V to the pfn delivery from the
prostate study

42

Axial

Sagittal

(b)

(c)

(d)

Figure 26 (continued)
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(a)

(b)

(c)

Figure 27. DVH comparison between the planned (solid) and reconstructed (dashed)
for (a) planned delivery, (b) +30 msec offset to center leaf delivery, (c) +30
msec offset to all leaves delivery and (d) +0.7 V to the pfn offset delivery
from the prostate study
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(d)

Figure 27 (continued).

3.3.3

Lung Plan

For the lung study, isodose lines of the reconstructed dose from a planned delivery
matched the planned isodose lines (Figure 28a) with their DVHs having small differences
(Figure 29a). The delivery with an intentional center leaf offset of -30 msec led to a decrease in
dose throughout the phantom and especially along the central axis of the phantom (Figure 28b).
Compared to the prostate delivery with an intentional center leaf offset of +30 msec, this delivery
has a greater effect in the delivered dose due to the PTV having a smaller volume. Therefore,
leaf open time errors have a greater contribution to the delivered dose of smaller PTV than to a
larger PTV. This is shown when comparing the DVHs of Figures 27b and 29b. For the delivery
with an intentional leaf open time offset of -30 msec to all leaves, the delivered dose to the PTV
is approximately -22% less than the planned (Figures 28c and 29c).
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Axial

Sagittal

(a)

(b)

(c)

Figure 28. Isodose [Gy] overlay of the planned (solid) and reconstructed (dashed) for
(a) planned delivery, (b) -30 msec offset to center leaf delivery and (c) -30
msec offset to all leave delivery from the lung study
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(a)

(b)

(c)

Figure 29. DVH comparison between the planned (solid) and reconstructed (dashed)
for (a) planned delivery, (b) -30 msec offset to center leaf delivery and (c) 30 msec offset to all leaves delivery from the lung study
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(c)

3.4

Aim 4: Comparison of the Measured Dose Versus Reconstructed Dose
3.4.1

Point Dose Comparison

Daily ion chamber measurements for each plan consisted of two readings. The readings
on any given day varied little, and their average value was used for comparison with the model.
Comparisons between the average measured dose and average reconstructed (DV) dose from
deliveries with no intentional offset of the H&N, prostate and lung plans are shown in Tables 5,
6 and 7, respectively.
Table 5.

Point dose comparison between the measured and the DV dose from DVPA
for the H&N plan with no offset (planned dose = 2.037 Gy)

Delivered Plan
(H&N)
Normal - Day 1
Normal - Day 2
Normal - Day 3
Normal - Day 4
Normal - Day 5
Normal - Day 6
Table 6.

Avg Measured
Dose [Gy]
2.068
2.056
2.087
2.040
2.030
2.054

Avg DV Dose
[Gy]
2.075
2.058
2.083
2.040
2.033
2.066

Diff.
0.3%
0.1%
-0.2%
0.0%
0.1%
0.6%

Point dose comparison between the measured and the DV dose from DVPA
for the prostate plan with no offset (planned dose = 2.063 Gy)

Delivered Plan
(prostate)
Normal - Day 1
Normal - Day 2
Normal - Day 3
Normal - Day 4
Normal - Day 5
Normal - Day 6
Normal - Day 7

Avg Measured
Dose [Gy]
2.060
2.061
2.071
2.051
2.065
2.046
2.054

Avg DV Dose
[Gy]
2.032
2.039
2.044
2.026
2.054
2.051
2.069
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Diff.
-1.4%
-1.0%
-1.3%
-1.2%
-0.5%
0.2%
0.7%

Table 7.

Point dose comparison between the measured and the DV dose from DVPA
for the prostate plan with no offset (planned dose = 2.022 Gy)

Delivered Plan
(lung)
Normal - Day 1

Avg Measured
Dose [Gy]
1.975

Avg DV Dose
[Gy]
1.958

-0.9%

Normal - Day 2

1.970

1.954

-0.8%

Normal - Day 3

1.969

1.973

0.2%

Normal - Day 4

1.972

1.990

0.9%

Normal - Day 5

1.951

1.970

1.0%

Diff.

The results show agreement between the DVPA model and the measured dose to within
2% for all cases studied. The slightly lower dose measured for the lung treatment plan was also
reproduced by the DVPA software in Table 8.
Table 8.

Summary of the mean differences and their standard deviation over all
measurements delivered with no intentional offset for each plan

Plan

Mean
±
Diff. (%)

σ

H&N

0.12

±

0.34

Prostate

-0.64

±

0.82

Lung

0.08

±

1.66

Figures 30 through 32 displays the statistical variations and comparisons of the measured
and reconstructed point dose data relative to the planned point dose for all plans.
Comparisons between measured and reconstructed doses for deliveries with intentional
leaf open time errors are shown in Tables 9, 10 and 11. The results show that the DVPA is able
to predict the delivered dose to within 2% for all three plans that had variable leaf open time
offsets.
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H&N (planned delivery)
2.10
2.09

Dose [Gy]

2.08
2.07
2.06

Measured Dose

2.05

DV Dose
Planned Dose

2.04
2.03
2.02
0

1

3

2

4

5

6

7

Day

Figure 30. Statistical variations of the measured
easured and reconstructed doses (DV dose)
with no intentional offset in the deliveries for the H&N plan

Prostate (planned delivery)
2.08
2.07
2.06
2.05

Measured Dose
DV Dose

2.04

Planned Dose

2.03
2.02
0

1

2

3

4

5

6

7

8

Day

Figure 31. Statistical variations of the measured and reconstructed doses (DV dose)
with no intentional offset in the deliveries for the prostate plan
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Lung (planned delivery)
2.03
2.02
2.01
2.00
1.99
Measured Dose

1.98

DV Dose

1.97

Planned Dose

1.96
1.95
1.94
0

1

2

3

4

5

6

Day

Figure 32. Statistical variations of the measured and reconstructed doses (DV dose)
with no intentional offset in the deliveries for the lung plan

Table 9.

Point dose comparison between the measured and the re
reconstructed
constructed dose
from DVPA for the H&N plan with intentional leaf open time offset (planned
dose = 2.037 Gy)

Delivered Plan
(H&N)

Avg Measured
Dose [Gy]

Avg DV Dose
[Gy]

Diff.

All leaves -10 ms

1.90

1.897

0.1%

All leaves +10 ms

2.22

2.215

-0.2%

All leaves -30 ms

1.63

1.643

0.8%

All leaves +30 ms

2.49

2.498

0.5%

Leaf #27 -10 ms

2.07

2.062

-0.4%

Leaf #27 +10 ms

2.09

2.081

-0.5%

Leaf #33 +10 ms

2.09

2.081

-0.4%

51

Table 10. Point dose comparison between the measured and the reconstructed dose
from DVPA for the prostate plan with intentional leaf open time offset
(planned dose = 2.063 Gy)

Delivered Plan
(Prostate)

Avg Measured
Dose [Gy]

Avg DV Dose
[Gy]

Diff.

All leaves -10 ms

1.91

1.882

-1.5%

All leaves +10 ms

2.20

2.177

-1.1%

All leaves -30 ms

1.60

1.582

-1.1%

All leaves +30 ms

2.50

2.471

-1.0%

Leaf #33 -10 ms

2.01

1.983

-1.4%

Leaf #33 +10 ms

2.11

2.101

-0.2%

Leaf #33 -30 ms

1.90

1.860

-2.1%

Leaf #33 +30 ms

2.21

2.226

0.7%

Table 11. Point dose comparison between the measured and the reconstructed dose
from DVPA for the lung plan with intentional leaf open time offset (planned
dose = 2.022 Gy)

Delivered Plan
(Lung)

Avg Measured
Dose [Gy]

Avg DV Dose
[Gy]

Diff.

All leaves -10 ms

1.84

1.832

-0.4%

All leaves +10 ms

2.12

2.098

-1.0%

All leaves -30 ms

1.57

1.567

-0.2%

All leaves +30 ms

2.39

2.367

-1.0%

Leaf #32-33 -10ms

1.86

1.846

-0.8%

Leaf #32-33 +10ms

2.09

2.076

-0.7%

Leaf #32-33 -30ms

1.63

1.599

-1.6%

Leaf #32-33 +30ms

2.33

2.312

-0.8%
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Table 12 summarizes the range of dose differences of each plan for intentional leaf open
time offsets deliveries versus its reconstructed dose.
Table 12. Summary of the mean differences and their standard deviation over all
measurements delivered with intentional leaf open time offset for each plan

Mean
±
Diff. (%)

Plan

σ

H&N

0.12

±

0.34

Prostate

-0.64

±

0.82

Lung

0.08

±

1.66

Comparisons between measured and reconstructed doses for deliveries with intentional
output errors are shown in Table 13 and 14.
Table 13. Point dose comparison between the measured and the reconstructed dose
from DVPA for the prostate plan with intentional output offset (planned dose
= 2.063 Gy)

Delivered Plan
(Prostate)

Avg Measured
Dose [Gy]

Avg DVPA
Dose [Gy]

Diff.

Output +0.6%

2.08

2.072

-0.4%

Output +1.1%

2.09

2.085

-0.2%

Output +2.2%

2.11

2.097

-0.6%

Output +3.9%

2.15

2.127

-0.9%

Output -3.9%

1.96

1.969

0.4%
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Table 14. Point dose comparison between the measured and the reconstructed dose
from DVPA for the prostate plan with intentional output offset (planned dose
= 2.022 Gy)

Delivered Plan
(Lung)

Avg Measured
Dose [Gy]

Avg DVPA
Dose [Gy]

Diff.

Output -2.7%

1.91

1.901

-0.2%

Output +2.7%

2.03

2.007

-1.1%

Output +3.9%

2.07

2.048

-0.8%

3.4.2

Dose Distribution Comparison

Quantitative comparisons of distributions between calculated and measured film doses
was achieved using the gamma statistic24 computed on the TomoTherapy TPS Alpha6. Fifty-six
films were digitized, converted to dose and read into the TPS in this study. Figure 33a display
the gamma between the measured film dose and computed planned dose for a H&N planned
delivery. The grayscale shows the background of the film and the color-wash represents the
gamma index. Figure 33b is an isodose overlay in unit of Gy for the same dose distributions,
where the solid lines represent film dose and the dashed represent planned dose. Figure 34
displays the profiles of the film and planned doses taken along the white crosshair in Figure 33a.
Comparison between the film and reconstructed dose for the same H&N planned delivery is
shown in Figure 35. Refer to Appendix A, Appendix B and Appendix C for additional dose
distribution comparisons of the H&N, prostate and lung study, respectively.
For each film, a gamma distribution histogram was computed for all points contained
within the selected region of interest. An example of the histogram is shown in Figure 37, which
displays the computed cumulative gamma distribution. This graph plots the percentage of dose
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points within the selected region (y-axis) which exceed a given gamma value (x-axis). An ideal
cumulative histogram would have 100% at a gamma of 0, with 0% for all other points. In Figure
37, the percentage of points which fail the given criteria (i.e., γ < 1) is seen to be about 2% from
the graph. Since the TomoTherapy TPS did not have the ability to export the gamma
distribution, important points on the curve were recorded for each comparison. In addition to the
percentage of points passing the criteria, the gamma index for which 90% and 95% of the
measured points selected were recorded in order to get a sense of the shape of the curve in Figure
37 without having to display a figure for every gamma distribution.
Tables 15, 16 and 17 contain data that were taken from gamma distribution histograms of
the H&N, prostate and lung plans, respectively. In general, the tables show that the DVPA
software accurately predicts the dose distribution both for unmodified and modified deliveries.
The percentage of points which pass the criteria exceeds 96% for all measured plans for both the
H&N and lung deliveries. The agreements for the prostate treatment plan deliveries were not as
good, in one case being as low as 72.74%.
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(a)

(b)

Figure 33. (a) Gamma display and (b) isodose distribution of a film (solid) vs. planned
(dashed) doses from the H&N plan delivery with no intentional offset
VERTICAL DOSE PROFILE

HORIZONTAL DOSE PROFILE

Figure 34. Dose profiles of the film (red) and planned (blue) in reference to the
white crosshair in Figure 33a
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(a)

(b)

Figure 35. (a) Gamma display and (b) isodose distribution of a film (solid) vs.
reconstructed (dashed) doses from the H&N plan delivery with no
intentional offset
VERTICAL DOSE PROFILE

HORIZONTAL DOSE PROFILE

Figure 36. Dose profiles of the film (red) and reconstructed (blue) comparison in
reference to the white crosshair in Figure 35a
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Figure 37. Illustration of the gamma distribution histogram taken over a selected
region of interest

Table 15. Summary of the gamma distribution from film versus reconstructed
doses for the H&N plan
Delivered Plan

% of pixel with
Gamma < 1

Gamma index
@ 10%

Gamma index
@ 5%

Normal - Day 1

97.9%

0.63

0.80

Normal - Day 2

97.9%

0.62

0.80

Normal - Day 3

99.0%

0.60

0.73

Normal - Day 4

96.4%

0.68

0.90

Normal - Day 5

98.3%

0.66

0.80

All leaves -10 ms

97.1%

0.65

0.85

All leaves +10 ms

98.5%

0.65

0.80

Leaf #27 -10 ms

98.4%

0.67

0.81

Leaf #27 +10 ms

97.8%

0.71

0.85
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Table 16. Summary of the gamma distribution from film versus reconstructed
doses for the prostate plan
Delivered Plan

% of pixel with
Gamma < 1

Gamma
index @ 10%

Gamma
index @ 5%

Prostate - Day 1 (#1)

91.1%

0.97

1.10

Prostate - Day 1 (#2)

90.9%

0.98

1.09

Prostate - Day 2 (#1)

95.4%

0.86

0.99

Prostate - Day 2 (#2)

97.5%

0.76

0.89

Prostate - Day 3 (#1)

89.1%

1.01

1.14

Prostate - Day 3 (#2)

92.0%

0.96

1.08

Prostate - Day 4 (#1)

87.8%

1.04

1.17

Prostate - Day 4 (#2)

89.8%

1.00

1.13

All leaves +10 ms (#1)

95.7%

0.84

0.97

All leaves +10 ms (#2)

95.4%

0.84

0.98

All leaves -10 ms (#1)

93.2%

0.92

1.06

All leaves -10 ms (#2)

96.9%

0.83

0.94

All leaves +30 ms (#1)

96.1%

0.79

0.94

All leaves +30 ms (#2)

94.5%

0.89

1.01

All leaves -30 ms (#1)

90.1%

1.00

1.09

All leaves -30 ms (#2)

89.5%

1.01

1.11

Leaf 32-33 +10 ms (#1)

94.2%

0.88

1.03

Leaf 32-33 +10 ms (#2)

92.4%

0.95

1.07

Leaf 32-33 -10 ms (#1)

95.1%

0.87

0.99

Leaf 32-33 -10 ms (#2)

96.7%

0.82

0.93

Leaf 32-33 +30 ms (#1)

91.0%

0.97

1.12

Leaf 32-33 +30 ms (#2)

90.8%

0.98

1.13

Leaf 32-33 -30 ms (#2)

89.4%

1.01

1.14
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Table 17. Summary of the gamma distribution from film versus reconstructed
doses for the prostate plan
Delivered Plan

% of pixel with
Gamma < 1

Gamma index
@ 90%

Gamma index
@ 95%

Lung - Day 1 (#1)

99.9%

0.50

0.58

Lung - Day 1 (#2)

100.0%

0.47

0.54

Lung - Day 2 (#1)

99.8%

0.55

0.64

Lung - Day 2 (#2)

99.9%

0.63

0.71

Lung - Day 3 (#1)

99.4%

0.53

0.62

Lung - Day 4 (#1)

98.6%

0.66

0.78

All leaves -10 ms (#1)

100.0%

0.44

0.50

All leaves -10 ms (#2)

100.0%

0.37

0.42

All leaves +10 ms (#1)

100.0%

0.46

0.52

All leaves +10 ms (#2)

99.9%

0.44

0.50

All leaves -30 ms (#1)

100.0%

0.38

0.45

All leaves -30 ms (#2)

100.0%

0.34

0.41

All leaves +30 ms (#1)

100.0%

0.49

0.56

All leaves +30 ms (#2)

98.6%

0.75

0.84

Leaf 32-33 -10 ms (#1)

99.9%

0.56

0.63

Leaf 32-33 -10 ms (#2)

99.8%

0.58

0.65

Leaf 32-33 +10 ms (#1)

99.4%

0.67

0.76

Leaf 32-33 +10 ms (#2)

99.7%

0.60

0.69

Leaf 32-33 -30 ms (#1)

99.8%

0.57

0.65

Leaf 32-33 -30 ms (#2)

99.8%

0.56

0.64

Leaf 32-33 +30 ms (#1)

97.0%

0.76

0.90

Leaf 32-33 +30 ms (#2)

96.6%

0.77

0.90
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CHAPTER 4. CONCLUSIONS
4.1

Conclusions
The purpose of this study was to verify that the method used for DV can determine the

actual dose delivered during treatment to within 2% for point dose measurements in the PTV and
a gamma of less than 1.0 to at least 90% of a selected region for planar dose distribution
measurements. The investigated method accounted for variations in machine delivery due to
beam output and/or leaf open time errors to determine the effective leaf open times for a given
treatment delivery. A DR is then computed using the energy fluence determined by the effective
leaf open times.
The following aims were used to determine the accuracy of the investigated method. For
Aim 1, three treatment plans were generated using a homogenous cylindrical phantom
(TomoPhantom). Contours from a H&N, prostate and lung patients were copied onto the
phantom. Planning parameters and optimization used standard clinical protocols. The results for
each plan resembled those of clinical patient plans.
In Aim 2, plans were delivered and measured twice per day for several days to observe
the statistical variations in the delivery. In addition to the planned delivery, each plan were
delivered with intentional offsets in the leaf open times and beam output. Detector data were
extracted after each delivery to be used to determine the effective leaf open times.
Aim 3 consisted of using the effective leaf open times to generate the reconstructed dose
of a delivery. It was shown that the method of dose reconstruction based on DV was able to
account for changes in the delivery due to intentional offsets in leaf open times and/or beam
output. Increasing the leaf open time to all leaves, for an entire delivery, lead to a reconstructed
dose that has a higher dose to all structures relative to the planned dose. Similarly, decreasing
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the leaf open time of the center two leaves lead to a lower reconstructed dose along the central
axis of the phantom relative to the planned dose.
In Aim 4, comparisons were made between all measured dose and reconstructed dose.
For point dose comparisons, differences between ion chamber measurements and reconstructed
doses of all deliveries ranged from -2.1% to 0.9%. With the exception of one measurement
having a difference of greater than 2% from the reconstructed dose, a majority of the differences
were approximately -1%. For dose distribution comparisons, differences between film
measurements and reconstructed doses for nearly all deliveries had a gamma index of less than 1
for over 90% of the region of interest.
The results from this study showed that the DV method employed by TomoTherapy
DVPA software was able to reconstruct the delivered dose to within 2% of the measured point
dose (using an ionization chamber) for the three plans with and without intentional delivery
errors. Dose distribution comparison between the film and DVPA reconstructed dose showed
significant improvements in agreement when compared to that between the film and planned
dose. Gamma index distribution between the film and DVPA dose showed that over 85% of the
dose distribution within the selected region for the three plans had a gamma value of less than
1.0.
4.2

Recommendation
This study did not include MVCT images acquired prior to deliveries for dose

reconstruction. For actual patient treatments, daily variations in setup and anatomical position
and/or shape exist. Therefore, use of the daily MVCT image is needed along with DV to
properly reconstruct dose that was delivered. This requires that the IVDTs for both the kVCT
and MVCT be accurate such that scans of the same object using either modality will result in the
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same image (in terms of image value). Monthly quality assurance should be put in place to keep
both IVDTs up-to-date. This would involve scanning a heterogeneous phantom, with known
densities, on both a kVCT (used for diagnostic and treatment planning) and MVCT (treatment
machine) scanner.
4.3

Future Study
This study showed that DV and DR can be used to accurately determine the delivered

dose to a typical clinical treatment delivery. These tools provide the option to implement
adaptive radiotherapy into a patient’s treatment plan during the course of treatment to correct for
any deviations from the planned dose. However, to properly utilize the full potential of adaptive
radiotherapy, it is important to reconstruct the delivered dose based on the image of the patient
during treatment (IGRT). A deformable registration will need to be applied to this current image
in order to get an accurate idea of the dose delivered to the targets and critical structures.
By using the recommendation mentioned previously along with a system capable of
deformable registration, DV and DR, one could perform clinical patient study to determine the
importance of adaptive radiotherapy for helical tomotherapy. This would require a DR for every
delivery of a patient’s treatment. After the final treatment, a cumulative dose can be computed
by summing the DRs for each delivery and comparing it to the planned dose.
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APPENDIX A: H&N DOSE DISTRIBUTION COMPARISONS
Additional dose distribution comparisons of the H&N plan for various deliveries.

(a)

(b)

Figure A1. (a) Gamma display and (b) isodose distribution of a film (solid) vs. planned
(dashed) dose from the H&N plan delivery with +10 msec center leaf offset
VERTICAL DOSE PROFILE

HORIZONTAL DOSE PROFILE

Figure A2. Dose profile of the film (red) and planned (blue) in reference to the white
crosshair in Figure A1a
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(a)

(b)

Figure A3. (a) Gamma display and (b) isodose distribution of a film (solid) vs.
reconstructed (dashed) dose from the H&N plan delivery with +10 msec
center leaf offset
VERTICAL DOSE PROFILE

HORIZONTAL DOSE PROFILE

Figure A4. Dose profile of the film (red) and reconstructed (blue) in reference to the
white crosshair in Figure A3a
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(a)

(b)

Figure A5. (a) Gamma display and (b) isodose distribution of a film (solid) vs. planned
(dashed) dose from the H&N plan delivery with +10 msec all leaves offset
VERTICAL DOSE PROFILE

HORIZONTAL DOSE PROFILE

Figure A6. Dose profile of the film (red) and planned (blue) in reference to the white
crosshair in Figure A5a
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(a)

(b)

Figure A7. (a) Gamma display and (b) isodose distribution of a film (solid) vs.
reconstructed (dashed) dose from the H&N plan delivery with +10 msec all
leaves offset
VERTICAL DOSE PROFILE

HORIZONTAL DOSE PROFILE

Figure A8. Dose profile of the film (red) and reconstructed (blue) in reference to the
white crosshair in Figure A7a
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APPENDIX B: PROSTATE DOSE DISTRIBUTION COMPARISONS
Dose distribution comparisons for multiple deliveries of the prostate plan.

(a)

(b)

Figure B1. (a) Gamma display and (b) isodose distribution of a film (solid) vs. planned
(dashed) dose from the prostate plan delivery with no intentional offset
(5/1/08)

VERTICAL DOSE PROFILE

HORIZONTAL DOSE PROFILE

Figure B2. Dose profile of the film (red) and planned (blue) in reference to the white
crosshair in Figure B1a
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(a)

(b)

Figure B3. (a) Gamma display and (b) isodose distribution of a film (solid) vs.
reconstructed (dashed) dose from the prostate plan delivery with no
intentional offset (5/1/08)
VERTICAL DOSE PROFILE

HORIZONTAL DOSE PROFILE

Figure B4. Dose profile of the film (red) and reconstructed (blue) in reference to the
white crosshair in Figure B3a
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(a)

(b)

Figure B5. (a) Gamma display and (b) isodose distribution of a film (solid) vs. planned
(dashed) dose from the prostate plan delivery with no intentional offset
(5/8/08)
VERTICAL DOSE PROFILE

HORIZONTAL DOSE PROFILE

Figure B6. Dose profile of the film (red) and planned (blue) in reference to the white
crosshair in Figure B5a
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(a)

(b)

Figure B7. (a) Gamma display and (b) isodose distribution of a film (solid) vs.
reconstructed (dashed) dose from the prostate plan delivery with no
intentional offset (5/8/08)
VERTICAL DOSE PROFILE

HORIZONTAL DOSE PROFILE

Figure B8. Dose profile of the film (red) and reconstructed (blue) in reference to the
white crosshair in Figure B7a
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(a)

(b)

Figure B9. (a) Gamma display and (b) isodose distribution of a film (solid) vs. planned
(dashed) dose from the prostate plan delivery with +30 msec center leaf
offset (5/8/08)
VERTICAL DOSE PROFILE

HORIZONTAL DOSE PROFILE

Figure B10. Dose profile of the film (red) and planned (blue) in reference to the white
crosshair in Figure B9a
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(a)

(b)

Figure B11. (a) Gamma display and (b) isodose distribution of a film (solid) vs.
reconstructed (dashed) dose from the prostate plan delivery with +30 msec
center leaf offset (5/8/08)
VERTICAL DOSE PROFILE

HORIZONTAL DOSE PROFILE

Figure B12. Dose profile of the film (red) and reconstructed (blue) comparison in
reference to the white crosshair in Figure B11a
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(a)

(b)

Figure B13. (a) Gamma display and (b) isodose distribution of a film (solid) vs. planned
(dashed) dose from the prostate plan delivery with +30 msec all leaves
offset (5/1/08)
VERTICAL DOSE PROFILE

HORIZONTAL DOSE PROFILE

Figure B14. Dose profile of the film (red) and planned (blue) in reference to the white
crosshair in Figure B13a
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(a)

(b)

Figure B15. (a) Gamma display and (b) isodose distribution of a film (solid) vs.
reconstructed (dashed) dose from the prostate plan delivery with +30 msec
all leaves offset (5/1/08)
VERTICAL DOSE PROFILE

HORIZONTAL DOSE PROFILE

Figure B16. Dose profile of the film (red) and reconstructed (blue) in reference to the
white crosshair in Figure B15a
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(a)

(b)

Figure B17. (a) Gamma display and (b) isodose distribution of a film (solid) vs. planned
(dashed) dose from the prostate plan delivery with -30 msec all leaves offset
(5/1/08)

VERTICAL DOSE PROFILE

HORIZONTAL DOSE PROFILE

Figure B18. Dose profile of the film (red) and planned (blue) in reference to the white
crosshair in Figure B17a
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(a)

(b)

Figure B19. (a) Gamma display and (b) isodose distribution of a film (solid) vs.
reconstructed (dashed) dose from the prostate plan delivery with -30 msec
all leaves offset (5/1/08)

VERTICAL DOSE PROFILE

HORIZONTAL DOSE PROFILE

Figure B20. Dose profile of the film (red) and reconstructed (blue) in reference to the
white crosshair in Figure B19a
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APPENDIX C: LUNG DOSE DISTRIBUTION COMPARISONS

(a)

(b)

Figure C1. (a) Gamma display and (b) isodose distribution of a film (solid) vs. planned
(dashed) dose from the lung plan delivery with no intentional offset
(5/30/08)

VERTICAL DOSE PROFILE

HORIZONTAL DOSE PROFILE

Figure C2. Dose profile of the film (red) and planned (blue) in reference to the white
crosshair in Figure C1a
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(a)

(b)

Figure C3. (a) Gamma display and (b) isodose distribution of a film (solid) vs.
reconstructed (dashed) dose from the lung plan delivery with no intentional
offset (5/30/08)

VERTICAL DOSE PROFILE

HORIZONTAL DOSE PROFILE

Figure C4. Dose profile of the film (red) and reconstructed (blue) in reference to the
white crosshair in Figure C3a
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(a)

(b)

Figure C5. (a) Gamma display and (b) isodose distribution of a film (solid) vs. planned
(dashed) dose from the lung plan delivery with +30 msec center leaf offset
(6/3/08)

VERTICAL DOSE PROFILE

HORIZONTAL DOSE PROFILE

Figure C6. Dose profile of the film (red) and planned (blue) in reference to the white
crosshair in Figure C5a
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(a)

(b)

Figure C7. (a) Gamma display and (b) isodose distribution of a film (solid) vs.
reconstructed (dashed) dose from the lung plan delivery with +30 msec
center leaf offset (6/3/08)

VERTICAL DOSE PROFILE

HORIZONTAL DOSE PROFILE

Figure C8. Dose profile of the film (red) and reconstructed (blue) in reference to the
white crosshair in Figure C7a
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(b)

Figure C9. (a) Gamma display and (b) isodose distribution of a film (solid) vs. planned
(dashed) dose from the lung plan delivery with +30 msec all leaves offset
(5/30/08)

VERTICAL DOSE PROFILE

HORIZONTAL DOSE PROFILE

Figure C10. Dose profile of the film (red) and planned (blue) in reference to the white
crosshair in Figure C9a
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Figure C11. (a) Gamma display and (b) isodose distribution of a film (solid) vs.
reconstructed (dashed) dose from the lung plan delivery with +30 msec
center leaf offset (6/3/08)

VERTICAL DOSE PROFILE

HORIZONTAL DOSE PROFILE

Figure C12. Dose profile of the film (red) and reconstructed (blue) in reference to the
white crosshair in Figure C11a
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